U.S. markets open in 3 hours 36 minutes

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.4900-0.5100 (-12.75%)
At close: 04:00PM EST
3.5700 +0.08 (+2.29%)
Pre-Market: 05:41AM EST

NRx Pharmaceuticals, Inc.

1201 Orange Street
Suite 600
Wilmington, DE 19801
United States
484 254 6134

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Jonathan C. Javitt M.D., M.P.H.Co-Founder, Chairman & CEO471.05kN/A1957
Mr. Robert Besthof M.I.M.Head of Operations & Chief Commercial Officer and Patient Officer214.38kN/A1966
Prof. Daniel C. JavittCo-Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Mr. James H. Brandon CPAActing Chief Financial OfficerN/AN/A1956
Ms. Alessandra Daigneault Esq.Chief Corp. Officer, Gen. Counsel, Sec. & Acting TreasurerN/AN/A1964
Mr. Jack HirschfieldSr. Director of Corp. Communications & External AffairsN/AN/AN/A
Dr. Philip T. LavinChief MethodologistN/AN/A1947
Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Sr. ScientistN/AN/AN/A
Mr. Randolph Guggenheimer IIIChief Bus. OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Corporate Governance

NRx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.